Esterase inhibition attribute of grapefruit juice leading to a new drug interaction

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1023-1031

  Li, Ping ^a,b   Callery, Patrick S ^b   Gan, Liang Shang ^a   Balani, Suresh K ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENYLPHOSPHATASE; CYTOCHROME P450 3A; ENALAPRIL; ENALAPRILAT; ESTERASE; LOVASTATIN ACID; MEVINOLIN; PHENYLACETIC ACID DERIVATIVE; S 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG METABOLISM; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME STABILITY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BEVERAGES; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CITRUS PARADISI; ENALAPRIL; ENZYME INHIBITORS; ESTERASES; FOOD-DRUG INTERACTIONS; FRUIT; HUMANS; HYDROLYSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; LIVER; LOVASTATIN; MALE; NITROPHENOLS; RATS; RATS, SPRAGUE-DAWLEY; SUBCELLULAR FRACTIONS; SWINE;

CITRUS X PARADISI; RATTUS; SUS;

EID: 34250782654     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013268     Document Type: Article

References (25)

1. Bailey DG, Spence JD, Edgar B, Bayliff CD, and Arnold JM (1989) Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 12:357-362.
2. Bailey DG, Spence JD, Munoz C, and Arnold JM (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268-269.
3. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, and Smolarek TA (2005) Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537-546.
4. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
5. Drummer OH, Nicolaci J, and Iakovidis D (1990) Biliary excretion and conjugation of diacid angiotensin-converting enzyme inhibitors. J Pharmacol Exp Ther 252:1202-1206.
6. Ducharme MP, Warbasse LH, and Edwards DJ (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57:485-491.
7. Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, and Vickers S (1989) The physiological disposition of lovastatin. Drug Metab Dispos 17:166-173.
8. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, and Duggan DE (1993) Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 21:1003-1011.
9. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, and Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259.
10. Hockings N, Ajayi AA, and Reid JL (1986) Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol 21:341-348.
11. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, and Sawada Y (2004) Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856-864.
12. Kantola T, Kivisto KT, and Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397-402.
13. Morrison RA, Chong S, Marino AM, Wasserman MA, Timmins P, Moore VA, and Irwin WJ (1996) Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies. Pharm Res 13:1078-1082.
14. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, and Hasegawa R (2005) Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 28:677-694.
15. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, et al. (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228-1233.
16. Tocco DJ, deLuna FA, Duncan AE, Vassil TC, and Ulm EH (1982) The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos 10:15-19.
17. Van Gelder J, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P (1999) Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature - identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharm Res 16:1035-1040.
18. Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, and Augustijns P (2000) Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 28:1394-1396.
19. Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, and Augustijns P (2002) Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 30:924-930.
20. Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M, and Merkx I (2003) Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: gut hydrolysis of lovastatin is twice that of simvastatin. Scientific World Journal 11:1332-1343.
21. Vyas KP, Kari PH, Prakash SR, and Duggan DE (1990) Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab Dispos 18:218-222.
22. Walker CH and Mackness MI (1983) Esterase: problems of identification and classification. Biochem Pharmacol 32:3265-3269.
23. Williams CFM (1985) Clinical significance of esterase in man. Clin Pharmacokinet 10:392-403.
24. Xia CQ, Liu N, Yang D, Miwa G, and Gan LS (2005) Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33:637-643.
25. Zhou S, Lim LY, and Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57-104.